Facon, T. Et Al. 2021. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15 .

Facon, T., Moreau, P., Martin, T. G., Spicka, I., Oriol, A., Koh, Y., ... Lim, A.(2021). Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15.

Facon, Thierry Et Al. "Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.," JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021

Facon, Thierry Et Al. "Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021

Facon, T. Et Al. (2021) . "Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15.

@article{article, author={Thierry Facon Et Al. }, title={Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2021}